Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
43 hedge funds and large institutions have $13.7M invested in Genocea Biosciences, Inc. in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 10 closing their positions.
10% less funds holding
Funds holding: 48 → 43 (-5)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
64% less capital invested
Capital invested by funds: $38.5M → $13.7M (-$24.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$206K |
| 2 |
VF
Virtu Financial
New York
|
+$35.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24.8K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$21.8K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$520K |
| 2 |
Millennium Management
New York
|
-$310K |
| 3 |
BC
Birchview Capital
Burlington,
Vermont
|
-$147K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$93.6K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$76K |
GNCA Hedge Fund Activity: Q4 2018 in Review
43 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q4 2018, worth a combined $13.7M — down 64% from $38.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GNCA and 5 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was DRW Securities, adding an estimated $206K. The largest seller was Vanguard Group, cutting an estimated $520K.
- 43 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q4 2018, down from 48 in Q3 2018.
- Funds reported $13.7M of Genocea Biosciences, Inc. stock for Q4 2018, down 64% quarter-over-quarter.
- 5 funds opened new Genocea Biosciences, Inc. positions in Q4 2018 and 10 closed out, a net change of -5 holders.
- The largest Genocea Biosciences, Inc. buyer in Q4 2018 was DRW Securities, an estimated $206K added.
- The largest Genocea Biosciences, Inc. seller in Q4 2018 was Vanguard Group, an estimated $520K sold.
Based on aggregated 13F filings for Q4 2018.